With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Cooperating Signaling Networks Regulate Cell Survival of Pediatric Ph-like ALL||University of Pennsylvania / Christian Hurtz, PhD||Young Investigator Grants||2018||Pennsylvania|
|Accessing Combinatorial Effect of PARP Inhibitor with DNA Damaging Agent in Rhabdomyosarcoma at Single Cell Resolution||Massachusetts General Hospital / Chuan Yan, PhD||Young Investigator Grants||2018||Massachusetts|
|Novel Antibodies to the C2-set Domain of CD33 for Acute Myeloid Leukemia Immunotherapy||Fred Hutchinson Cancer Research Center / Colin Godwin, MD||Young Investigator Grants||2018||Washington|
|Describing the Biological Impacts of Gain-of-function SAMD9 Mutations||Vanderbilt University Medical Center / Jason Schwartz, MD/PhD||Young Investigator Grants||2018||Tennessee|
|MYC-driven Core Regulatory Circuits in Neuroblastoma||Dana-Farber Cancer Institute / Mark Zimmerman, PhD||Young Investigator Grants||2018||Massachusetts|
|Divergent Core Transcriptional Regulatory Circuitries to Highlight Context-Specific Vulnerabilities in AML||Dana-Farber Cancer Institute / Maxim Pimkin, MD/PhD||Young Investigator Grants||2018||Massachusetts|
|Modeling and Therapeutic Targeting of p21-Activated Kinase Members in High-Risk Rhabdomyosarcoma||Baylor College of Medicine / Jason Yustein, MD/PhD||Innovation Grants||2018||Texas|
|Identifying New Therapeutic Targets in Fibrolamellar Hepatocellular Carcinoma||Stanford University / Julien Sage, PhD||Innovation Grants||2018||California|
|Targeting Oncogenic RAS in Pediatric Leukemia||Dana-Farber Cancer Institute / Loren Walensky, MD/PhD||Innovation Grants||2018||Massachusetts|
|Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia?||University of Utah / Michael Deininger, MD/PhD||Innovation Grants||2018||Utah|